

101.429-12 – including *Taq* polymerase, IFU-01  
 101.429-12u – without *Taq* polymerase, IFU-02

Visit <https://labproducts.caredx.com> for  
 “Instructions for Use” (IFU)

Lot No.: **0R2**

Lot-specific Information  
**Olerup SSP<sup>®</sup> HLA-A\*30**

<b>Product number:</b>	<b>101.429-12 – including <i>Taq</i> polymerase</b> <b>101.429-12u – without <i>Taq</i> polymerase</b>
<b>Lot number:</b>	<b>0R2</b>
<b>Expiry date:</b>	<b>2026-04-01</b>
<b>Number of tests:</b>	<b>12</b>
<b>Number of wells per test:</b>	<b>31+1</b>
<b>Storage - pre-aliquoted primers:</b>	<b>dark at -20°C</b>
- PCR Master Mix:	-20°C
- Adhesive PCR seals	RT
- Product Insert	RT

**This Product Description is only valid for Lot No. 0R2.**

Complete product documentation consists of generic Instructions for Use (IFU), lot specific Product Insert, Worksheet and Certificate.

**CHANGES COMPARED TO THE PREVIOUS OLERUP SSP<sup>®</sup>  
 HLA-A\*30 LOT (4L3)**

- The product documentation has been updated for new alleles of IMGT 3.47.0
- The kit resolution focuses on common and well documented (CWD) alleles<sup>1</sup>.

<sup>1</sup>As described in section Uniquely Identified Alleles.

The HLA-A\*30 primer set, specificity and interpretation tables have been updated for the HLA-A alleles described since the previous *Olerup SSP<sup>®</sup> HLA-A\*30* lot was made (Lot No. 4L3).

<sup>1</sup>S. J. Mack, P. Cano, J. A. Hollenbach et al.  
 Common and well-documented HLA alleles: 2012 update to the CWD catalogue. *Tissue Antigens*, 2013, 81, 194–203



**0197**

For *In Vitro* Diagnostic Use  
 MA123 v01 SSP PI Template  
 Date: April 2022 Rev. No: 00

**101.429-12** – including *Taq* polymerase, IFU-01  
**101.429-12u** – without *Taq* polymerase, IFU-02

Visit <https://labproducts.caredx.com> for  
**“Instructions for Use” (IFU)**

**Lot No.: 0R2**

**Lot-specific Information**

The primers of the wells detailed below have been exchanged, added or modified compared to the previous lot.

<b>Well</b>	<b>5'-primer</b>	<b>3'-primer</b>	<b>rationale</b>
15	-	Added	3'-primer added for the A*30:58 allele.
18	-	Added	3'-primer added for the A*30:38 allele.
19	-	Added	3'-primer added for the A*30:38 allele.
20	-	Added	3'-primer added for the A*30:58 allele.
28	Added	Added	Primer pair added for the A*30:54 allele.



**0197**

For *In Vitro* Diagnostic Use  
 MA123 v01 SSP PI Template  
 Date: April 2022 Rev. No: 00

101.429-12 – including *Taq* polymerase, IFU-01  
 101.429-12u – without *Taq* polymerase, IFU-02

Visit <https://labproducts.caredx.com> for  
 “Instructions for Use” (IFU)

Lot No.: **0R2**

**Lot-specific Information**

Well **32** contains Negative Control primer pairs, that will amplify the majority of the *Olerup SSP*<sup>®</sup> HLA Class I, DRB, DQB1, DPB1 and DQA1 amplicons as well as all the amplicons generated by the control primer pairs matching the human growth hormone gene.

HLA-specific PCR product sizes range from 75 to 200 base pairs.  
 The PCR product generated by the positive control primer pair is 200 base pairs.

Length of PCR product	105	200	105	80	75	80	85
<b>5'-primer<sup>1</sup></b>	<b>164</b>	<b>340</b>	<b>440</b>	<b>45</b>	<b>45</b>	<b>43</b>	<b>36</b>
	5'-CAC <sup>3'</sup>	5'-Agg <sup>3'</sup>	5'-TTA <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-TAC <sup>3'</sup>
							<b>36</b>
							5'-TAT <sup>3'</sup>
<b>3'-primer<sup>2</sup></b>	<b>231</b>	<b>2<sup>nd</sup> I</b>	<b>507</b>	<b>59</b>	<b>58</b>	<b>57</b>	<b>47</b>
	5'-TgC <sup>3'</sup>	5'-AAA <sup>3'</sup>	5'-TTg <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-ggC <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-ACA <sup>3'</sup>
							<b>48</b>
							5'-gCA <sup>3'</sup>
							<b>48</b>
							5'-gCC <sup>3'</sup>
							<b>52</b>
							5'-TgT <sup>3'</sup>
<b>A*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>B*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>C*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>DRB1</b>				<b>+</b>	<b>+</b>		
<b>DRB3</b>				<b>+</b>	<b>+</b>		
<b>DRB5</b>				<b>+</b>			
<b>DQB1</b>					<b>+</b>		
<b>DPB1</b>						<b>+</b>	
<b>DQA1</b>							<b>+</b>

<sup>1</sup>The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2<sup>nd</sup> or 3<sup>rd</sup> exon, matching the specificity-determining 3'-end of the primer is given. Nucleotide and codon numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>2</sup>The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2<sup>nd</sup> or 3<sup>rd</sup> exon or the 2<sup>nd</sup> intron, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide and codon numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.



**0197**

101.429-12 – including *Taq* polymerase, IFU-01  
 101.429-12u – without *Taq* polymerase, IFU-02

Visit <https://labproducts.caredx.com> for  
 “Instructions for Use” (IFU)

Lot No.: **0R2**

Lot-specific Information  
**PRODUCT DESCRIPTION**

**HLA-A\*30 SSP subtyping**

**CONTENT**

The primer set contains 5'- and 3'-primers for identifying the A\*30:01 to A\*30:200 alleles.

**PLATE LAYOUT**

Each test consists of 32 PCR reactions in a 32 well cut PCR plate

<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>8</b>
<b>9</b>	<b>10</b>	<b>11</b>	<b>12</b>	<b>13</b>	<b>14</b>	<b>15</b>	<b>16</b>
<b>17</b>	<b>18</b>	<b>19</b>	<b>20</b>	<b>21</b>	<b>22</b>	<b>23</b>	<b>24</b>
<b>25</b>	<b>26</b>	<b>27</b>	<b>28</b>	<b>29</b>	<b>30</b>	<b>31</b>	<b>NC</b>

The 32 well cut PCR plate is marked with ‘HLA-A\*30’ in silver/gray ink.  
 Well No. 1 is marked with ‘0R2’.

Wells 1 to 31 – HLA-A\*30 high resolution primers.

Well 32 – Negative Control (NC).

A faint row of numbers is seen between wells 1 and 2 or wells 7 and 8 of the PCR trays. These stem from the manufacture of the trays and should be disregarded.

The PCR plates are covered with a PCR-compatible foil.

**Please note:** When removing each 32 well PCR plate, make sure that the remaining plates stay covered. Use a scalpel or a similar instrument to carefully cut the foil between the plates.

**INTERPRETATION**

Due to the sharing of sequence motifs between HLA-A alleles non-HLA-A\*30 alleles will be amplified by some primer mixes. For further details see Specificity Table.

**UNIQUELY IDENTIFIED ALLELES**

All the HLA-A\*30 alleles, i.e. **A\*30:01 to A\*30:200 alleles**, recognized by the HLA Nomenclature Committee in January 2022<sup>1,2</sup> will be amplified by the primers in the HLA-A\*30 subtyping kit.

The HLA-A\*30 kit enables separation of the confirmed HLA-A\*30 alleles as listed in the IMGT/HLA database 3.26.0. An HLA allele is listed as confirmed by IMGT/HLA if it has been sequenced by more than a single laboratory or from multiple sources. Current allele confirmation status for HLA-A\*30 alleles is listed below.

The HLA-A\*30 kit also enables identification of many null and alternatively expressed alleles.



**0197**

For *In Vitro* Diagnostic Use  
 MA123 v01 SSP PI Template  
 Date: April 2022 Rev. No: 00

101.429-12 – including *Taq* polymerase, IFU-01  
 101.429-12u – without *Taq* polymerase, IFU-02

Visit <https://labproducts.caredx.com> for  
 “Instructions for Use” (IFU)

Lot No.: **0R2**

**Lot-specific Information**

The following HLA-A\*30 alleles can be distinguished by the different sizes of the HLA-specific PCR product:

Alleles	Primer mix
A*30:42, 30:81	26
A*30:54, 30:130N	28
A*30:56, 30:132N	27

<sup>1</sup>HLA-A alleles listed on the IMGT/HLA web page 2022-January-13, release 3.47.0, [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla).

<sup>2</sup>Alleles that have been deleted from or renamed in the official WHO HLA Nomenclature up to and including the last IMGT/HLA database release can be retrieved from web page <http://hla.alleles.org/alleles/deleted.html>.



**0197**

For *In Vitro* Diagnostic Use  
 MA123 v01 SSP PI Template  
 Date: April 2022 Rev. No: 00

101.429-12 – including *Taq* polymerase, IFU-01  
101.429-12u – without *Taq* polymerase, IFU-02

Visit <https://labproducts.caredx.com> for  
“Instructions for Use” (IFU)

Lot No.: **0R2**

Lot-specific Information

## ALLELE CONFIRMATION STATUS

Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>
A*30:01:01	Confirmed	A*30:11:02	Unconfirmed	A*30:52	Unconfirmed	A*30:92	Unconfirmed
A*30:01:02	Unconfirmed	A*30:12	Unconfirmed	A*30:53	Unconfirmed	A*30:93	Unconfirmed
A*30:01:03	Unconfirmed	A*30:13	Unconfirmed	A*30:54	Unconfirmed	A*30:94	Unconfirmed
A*30:01:04	Confirmed	A*30:14L	Unconfirmed	A*30:55	Unconfirmed	A*30:95	Unconfirmed
A*30:01:05	Unconfirmed	A*30:15	Unconfirmed	A*30:56	Confirmed	A*30:96	Unconfirmed
A*30:01:06	Unconfirmed	A*30:16	Confirmed	A*30:57	Unconfirmed	A*30:97	Unconfirmed
A*30:01:07	Unconfirmed	A*30:17	Confirmed	A*30:58	Unconfirmed	A*30:98	Unconfirmed
A*30:01:08	Unconfirmed	A*30:18	Unconfirmed	A*30:59N	Confirmed	A*30:99	Unconfirmed
A*30:01:09	Unconfirmed	A*30:19	Unconfirmed	A*30:60	Unconfirmed	A*30:100	Confirmed
A*30:01:10	Unconfirmed	A*30:20	Confirmed	A*30:61	Confirmed	A*30:102	Unconfirmed
A*30:01:11	Unconfirmed	A*30:22	Unconfirmed	A*30:62	Unconfirmed	A*30:103	Unconfirmed
A*30:02:01:01	Confirmed	A*30:23	Unconfirmed	A*30:63	Unconfirmed	A*30:104	Unconfirmed
A*30:02:01:02	Unconfirmed	A*30:24	Unconfirmed	A*30:64	Unconfirmed	A*30:106	Unconfirmed
A*30:02:01:03	Confirmed	A*30:25	Unconfirmed	A*30:65	Unconfirmed	A*30:107	Unconfirmed
A*30:02:02	Unconfirmed	A*30:26	Unconfirmed	A*30:66	Unconfirmed		
A*30:02:03	Confirmed	A*30:27N	Unconfirmed	A*30:67	Unconfirmed		
A*30:02:04	Confirmed	A*30:28	Unconfirmed	A*30:68	Unconfirmed		
A*30:02:05	Confirmed	A*30:29	Confirmed	A*30:69	Unconfirmed		
A*30:02:06	Confirmed	A*30:30	Confirmed	A*30:70N	Unconfirmed		
A*30:02:07	Unconfirmed	A*30:31	Confirmed	A*30:71	Confirmed		
A*30:02:08	Unconfirmed	A*30:32	Confirmed	A*30:72	Unconfirmed		
A*30:02:09	Unconfirmed	A*30:33	Unconfirmed	A*30:73N	Unconfirmed		
A*30:02:10	Unconfirmed	A*30:34	Unconfirmed	A*30:74	Unconfirmed		
A*30:02:11	Unconfirmed	A*30:35	Unconfirmed	A*30:75	Unconfirmed		
A*30:02:13	Confirmed	A*30:36	Confirmed	A*30:76N	Unconfirmed		
A*30:02:14	Unconfirmed	A*30:37	Unconfirmed	A*30:77	Unconfirmed		
A*30:02:15	Unconfirmed	A*30:38	Unconfirmed	A*30:78N	Confirmed		
A*30:02:16	Unconfirmed	A*30:39	Unconfirmed	A*30:79	Unconfirmed		
A*30:02:17	Unconfirmed	A*30:40	Confirmed	A*30:80	Confirmed		
A*30:02:18	Unconfirmed	A*30:41	Unconfirmed	A*30:81	Confirmed		
A*30:02:19	Unconfirmed	A*30:42	Confirmed	A*30:82	Unconfirmed		
A*30:03	Confirmed	A*30:43	Unconfirmed	A*30:83	Unconfirmed		
A*30:04:01	Confirmed	A*30:44	Unconfirmed	A*30:84	Unconfirmed		
A*30:04:02	Confirmed	A*30:45	Confirmed	A*30:85	Unconfirmed		
A*30:06	Unconfirmed	A*30:46	Unconfirmed	A*30:86	Unconfirmed		
A*30:07	Confirmed	A*30:47	Unconfirmed	A*30:87	Unconfirmed		
A*30:08	Confirmed	A*30:48	Unconfirmed	A*30:88	Unconfirmed		
A*30:09	Confirmed	A*30:49	Unconfirmed	A*30:89	Unconfirmed		
A*30:10	Confirmed	A*30:50	Unconfirmed	A*30:90	Confirmed		
A*30:11:01	Confirmed	A*30:51	Confirmed	A*30:91	Unconfirmed		

<sup>1</sup>Allele status “confirmed” or “unconfirmed” as listed on the IMGT/HLA web page 2016-October-14, release 3.26.0, [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla).

## RESOLUTION IN HOMO- AND HETEROZYGOTES

Results file with resolution in HLA-A\*30 homo- and heterozygotes is available upon request.



0197

For *In Vitro* Diagnostic Use  
MA123 v01 SSP PI Template  
Date: April 2022 Rev. No: 00

101.429-12 – including *Taq* polymerase, IFU-01  
 101.429-12u – without *Taq* polymerase, IFU-02

Visit <https://labproducts.caredx.com> for  
 “Instructions for Use” (IFU)

Lot No.: **0R2**

Lot-specific Information  
**SPECIFICITY TABLE**

**HLA-A\*30 SSP subtyping**

**Specificities and sizes of the PCR products of the 31+1 primer mixes used for HLA-A\*30 SSP subtyping**

Primer Mix	Size of spec. PCR product <sup>1</sup>	Size of control band <sup>2</sup>	Amplified HLA-A*30 alleles <sup>3</sup>	Other amplified HLA-A alleles
<b>1</b>	165 bp	<b>800 bp</b>	*30:01:01:01-30:01:11, 30:01:13-30:02:04, 30:02:06-30:03, 30:07-30:16, 30:18-30:20, 30:22-30:25, 30:27N-30:28, 30:31-30:45, 30:47-30:76N, 30:78N-30:89, 30:91-30:92, 30:94-30:98, 30:100-30:102, 30:104, 30:106-30:116, 30:118-30:122, 30:124-30:138, 30:140-30:149, 30:151-30:154, 30:156-30:163, 30:165-30:200	*02:52, 02:992, 03:43, 03:186, 23:46
<b>2</b>	205 bp	<b>800 bp</b>	*30:01:01:01-30:01:20, 30:08:01-30:08:02, 30:11:01-30:11:02, 30:14L-30:16, 30:18-30:20, 30:23-30:24, 30:26, 30:30-30:31, 30:35-30:44, 30:48-30:49, 30:53-30:56, 30:58-30:60, 30:62-30:63, 30:65, 30:71-30:75, 30:78N-30:79, 30:81-30:83, 30:86-30:87, 30:91-30:98, 30:102, 30:104, 30:106, 30:109-30:116, 30:118, 30:120, 30:122-30:123N, 30:126, 30:128-30:130N, 30:132N, 30:134-30:138, 30:140-30:143, 30:145N, 30:147-30:148, 30:154, 30:157, 30:159, 30:161, 30:163-30:165, 30:167-30:168, 30:170-30:171, 30:173, 30:176, 30:178N-30:181, 30:184Q-30:187, 30:190-30:192, 30:194-30:197N, 30:199	
<b>3<sup>6</sup></b>	210 bp	<b>800 bp</b>	*30:02:01:01-30:03, 30:07, 30:10, 30:12:01-30:13, 30:22, 30:25, 30:27N, 30:32-30:34, 30:45, 30:50-30:51, 30:57, 30:61, 30:64, 30:66-30:70N, 30:76N, 30:84-30:85, 30:88, 30:100-30:101Q, 30:107-30:108, 30:119, 30:121N, 30:124-30:125, 30:127, 30:133, 30:144, 30:146, 30:149, 30:151-30:153,	*01:304, 03:05:02, 03:231:01 <sup>w</sup> , 03:231:02, 03:323N, 11:24:01, 11:25:02, 34:02:02, 80:01:01:01-80:09N



**0197**

For *In Vitro* Diagnostic Use  
 MA123 v01 SSP PI Template  
 Date: April 2022 Rev. No: 00

101.429-12 – including *Taq* polymerase, IFU-01  
 101.429-12u – without *Taq* polymerase, IFU-02

Visit <https://labproducts.caredx.com> for  
 “Instructions for Use” (IFU)

Lot No.: **0R2**

Lot-specific Information

Lot No.: <b>0R2</b>			Lot-specific Information	
			30:156, 30:158N, 30:162, 30:166, 30:169, 30:174-30:175, 30:177, 30:182, 30:188-30:189, 30:193, 30:198, 30:200	
<b>4<sup>5</sup></b>	155 bp	1070 bp	*30:03, 30:11:01-30:11:02, 30:71, 30:163	*01:02:01:01-01:02:02, 01:20, 01:190, 33:108
<b>5</b>	150 bp	1070 bp	*30:04:01:01-30:04:03, 30:06, 30:17, 30:29, 30:46, 30:77, 30:90, 30:99, 30:103, 30:105, 30:117, 30:139, 30:150, 30:155	*02:52, 02:992, 03:82, 24:66, 24:308, 24:333, 68:06
<b>6<sup>4</sup></b>	245 bp 80 bp 185 bp 270 bp	1070 bp	*30:19 *30:06 *30:07 *30:51, 30:106	*02:121, 02:425, 02:517, 02:850, 02:937, 03:154:01, 23:47, 24:234, 24:339, 24:347:02, 29:06, 29:151, 31:51, 33:168, 68:14, 68:158, 68:264, <b>C*03:125<sup>w</sup>, C*03:176<sup>w</sup>, C*12:328</b>
<b>7<sup>4,7</sup></b>	90 bp 175 bp	1070 bp	*30:28, 30:131 *30:08:01-30:08:02, 30:150	*26:19
<b>8<sup>4</sup></b>	85 bp	<b>800 bp</b>	*30:10, 30:88	
<b>9</b>	180 bp	1070 bp	*30:01:01:01-30:02:29, 30:04:01:01-30:04:03, 30:06- 30:07, 30:09:01:01-30:10, 30:12:01-30:20, 30:23-30:54, 30:56-30:70N, 30:72-30:78N, 30:80-30:84, 30:86-30:132N, 30:134-30:149, 30:151, 30:153- 30:162, 30:164-30:165, 30:167- 30:176, 30:178N-30:185, 30:187-30:200	*24:124, 31:210
<b>10</b>	150 bp	1070 bp	*30:12:01-30:12:02, 30:18, 30:55, 30:152, 30:166	*01:07, 02:185, 02:601, 24:124, 26:19, 29:14, 31:01:02:01- 31:01:06, 31:01:08-31:01:33, 31:01:35-31:07, 31:09-31:43, 31:45-31:86, 31:88, 31:90- 31:141N, 31:143-31:194, 31:196-31:210
<b>11</b>	215 bp	<b>800 bp</b>	*30:01:01:01-30:04:03, 30:06, 30:09:01:01-30:20, 30:23-30:30, 30:32-30:54, 30:56-30:59N, 30:61-30:78N, 30:80-30:132N, 30:134-30:149, 30:151, 30:153- 30:165, 30:167-30:176, 30:178N-30:185, 30:187-30:200	*01:02:01:01 <sup>w</sup> -01:02:02 <sup>w</sup> , 01:20 <sup>w</sup> , 03:72, 11:88, 23:09 <sup>w</sup> , 23:51, 24:24, 24:67, 24:129 <sup>w</sup> , 24:145, 24:156, 24:191, 24:290, 24:392, 26:16, 29:37, 29:56, 31:210, 32:07, 33:119, 68:45, 68:117
<b>12<sup>5</sup></b>	190 bp	<b>800 bp</b>	*30:09:01:01-30:09:01:02, 30:35, 30:183	*01:244, 01:257, 03:42, 03:131, 03:133, 11:165, 31:03-31:04:02, 31:176, 31:179, 33:49, 33:144, 74:23
<b>13</b>	160 bp	1070 bp	*30:01:01:01-30:02:29, 30:04:01:01-30:04:03, 30:06- 30:10, 30:13-30:17,	



**0197**

For *In Vitro* Diagnostic Use  
 MA123 v01 SSP PI Template  
 Date: April 2022 Rev. No: 00



101.429-12 – including *Taq* polymerase, IFU-01  
 101.429-12u – without *Taq* polymerase, IFU-02

Visit <https://labproducts.caredx.com> for  
 “Instructions for Use” (IFU)

Lot No.: **0R2**

**Lot-specific Information**

Lot No.: <b>0R2</b>			Lot-specific Information	
			30:19-30:20, 30:23-30:40, 30:42-30:54, 30:56-30:70N, 30:72-30:84, 30:86-30:102, 30:104-30:151, 30:153-30:162, 30:164-30:165, 30:167-30:200	
<b>14<sup>5</sup></b>	210 bp 270 bp	1070 bp	*30:13, 30:16, 30:44, 30:46 *30:51, 30:106	*02:121, 02:425, 02:517, 02:850, 02:937, 03:154:01, 23:47, 24:234, 24:339, 24:347:02, 29:06, 29:151, 31:51, 33:168, 68:14, 68:158, 68:264, <b>C*03:125<sup>w</sup>, C*03:176<sup>w</sup>, C*12:328</b>
<b>15</b>	245 bp 290 bp	<b>800 bp</b>	*30:14L, 30:29, 30:122 *30:58	*01:124, 03:214, 11:414
<b>16<sup>5</sup></b>	235 bp 265 bp	1070 bp	*30:95 *30:15, 30:33	*26:187, 36:02 *01:399, 11:268
<b>17</b>	225 bp	1070 bp	*30:01:01:01-30:01:20, 30:11:01-30:11:02, 30:14L- 30:20, 30:23-30:26, 30:30- 30:31, 30:35-30:43, 30:48- 30:49, 30:52-30:54, 30:56, 30:58-30:60, 30:62-30:63, 30:65, 30:72-30:75, 30:78N, 30:81-30:83, 30:86-30:89, 30:91-30:98, 30:102, 30:104, 30:106, 30:109-30:116, 30:118, 30:120, 30:122-30:123N, 30:125-30:126, 30:128-30:132N, 30:134-30:138, 30:140-30:143, 30:145N, 30:147-30:148, 30:154, 30:159, 30:161, 30:163- 30:165, 30:167-30:168, 30:170- 30:173, 30:176, 30:178N- 30:181, 30:183-30:185, 30:187, 30:190-30:192, 30:194-30:197N, 30:199	*03:72, 11:88, 23:13, 24:07:01:01-24:07:04, 24:19, 24:24, 24:131, 24:288, 24:290, 24:294Q, 24:339, 24:347:01- 24:347:02, 24:387, 24:406, 24:453, 24:457, 24:477, 24:489, 24:510, 24:528, 24:541, 24:544, 29:37, 29:56, 68:45, 68:117
<b>18</b>	140 bp 210 bp	<b>800 bp</b>	*30:32, 30:38 *30:20, 30:71	
<b>19<sup>8</sup></b>	135 bp 200 bp 235 bp	1070 bp	*30:38, 30:70N *30:31 *30:77	*03:45
<b>20</b>	210 bp 285 bp	<b>800 bp</b>	*30:23 *30:34, 30:58	*01:124, 03:04:02-03:04:03, 03:214, 11:153:01, 11:414
<b>21</b>	150 bp 185 bp	1070 bp	*30:30, 30:100 *30:24	
<b>22</b>	180 bp 215 bp	<b>800 bp</b>	*30:36, 30:73N *30:27N	*03:323N
<b>23</b>	150 bp	1070 bp	*30:26, 30:76N, 30:123N	
<b>24<sup>4,7</sup></b>	105 bp 160 bp 210 bp	<b>800 bp</b>	*30:78N *30:22 *30:25, 30:57, 30:88, 30:90	*01:02:01-01:02:02, 01:20, 01:190



**0197**

For *In Vitro* Diagnostic Use  
 MA123 v01 SSP PI Template  
 Date: April 2022 Rev. No: 00

101.429-12 – including *Taq* polymerase, IFU-01  
 101.429-12u – without *Taq* polymerase, IFU-02

Visit <https://labproducts.caredx.com> for  
 “Instructions for Use” (IFU)

Lot No.: **0R2**

Lot-specific Information

Lot No.: <b>0R2</b>		Lot-specific Information		
<b>25<sup>7</sup></b>	160 bp 235 bp	1070 bp	*30:40, 30:76N *30:95	*26:187, 36:02
<b>26<sup>4</sup></b>	80 bp 190 bp 300 bp	1070 bp	*30:42 *30:121N *30:81	
<b>27</b>	145 bp 195 bp 465 bp	1070 bp	*30:56 *30:45 *30:132N	*11:166  *01:04:01:01N-01:04:01:02N, 03:21N, 11:21N, 23:07N, 24:11N
<b>28</b>	130 bp	1070 bp	*30:54, 30:89	*03:43, 03:82, 03:186, 11:113, 11:162, 24:66, 24:73, 24:106, 24:174, 24:308, 24:325, 24:333, 24:504, 32:101Q, <b>B*18:38,</b> <b>B*57:68, C*06:256</b>
<b>29</b>	465 bp 130 bp	1070 bp	*30:130N *30:59N, 30:61, 30:74	*01:57N, 01:88:02-01:88:03, 01:236, 02:156, 02:338, 02:952, 03:17:01, 03:171, 03:381N, 11:119:01-11:119:02, 11:209, 24:92, 24:458, 24:557, 68:103:01-68:103:02, 80:09N
<b>30<sup>4,5</sup></b>	190 bp 80 bp 155 bp	1070 bp	*30:73N, 30:121N *30:37 *30:123N	
<b>31</b>	200 bp	1070 bp	*30:80, 30:101Q	*23:104, <b>B*07:164, B*07:363,</b> <b>B*15:75</b>
<b>32<sup>9</sup></b>	-	-	<b>Negative Control</b>	

<sup>1</sup>Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of HLA-A\*30 SSP typings.

When the primers in a primer mix can give rise to HLA-specific PCR products of more than one length this is indicated if the size difference is more than 20 base pairs. Size differences of 20 base pairs or less are not given. For high resolution SSP kits, the alleles listed are specified according to amplicon length.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers.

PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherent feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

<sup>2</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

<sup>3</sup>For several HLA Class I alleles 1<sup>st</sup> and/or 4<sup>th</sup> exon(s) and beyond, as well as intron nucleotide sequences, are not available. In these instances it is not known whether some of the primers of the SSP sets are completely matched with the target sequences or not. Assumption is made that unknown sequences in these regions are conserved within allelic groups.



**0197**

For *In Vitro* Diagnostic Use  
 MA123 v01 SSP PI Template  
 Date: April 2022 Rev. No: 00

101.429-12 – including *Taq* polymerase, IFU-01  
 101.429-12u – without *Taq* polymerase, IFU-02

Visit <https://labproducts.caredx.com> for  
 “Instructions for Use” (IFU)

**Lot No.: 0R2**

**Lot-specific Information**

<sup>4</sup>HLA-specific PCR products shorter than 125 base pairs have a lower intensity and are less sharp than longer PCR products.

<sup>5</sup>Primer mixes 4, 12, 14, 16 and 30 may give rise to unspecific amplifications.

<sup>6</sup>Primer mix 3 may give rise to a lower yield of HLA-specific PCR product than the other A\*30 primer mixes.

<sup>7</sup>Primer mixes 7, 24 and 25 may have a tendency of giving rise to primer oligomer formation.

<sup>8</sup>In primer mix 19, the positive control band may be weaker than for other HLA-A\*30 primer pairs

<sup>9</sup>Primer mix 32 contains a negative control, which will amplify the majority of HLA amplicons as well as the amplicons generated by the control primer pairs matching the human growth hormone gene. HLA-specific PCR product sizes range from 75 to 200 base pairs and the PCR product generated by the HGH positive control primer pair is 200 base pairs.

Abbreviations

w: might be weakly amplified.



**0197**

For *In Vitro* Diagnostic Use  
 MA123 v01 SSP PI Template  
 Date: April 2022 Rev. No: 00

101.429-12 – including *Taq* polymerase, IFU-01  
101.429-12u – without *Taq* polymerase, IFU-02

Visit <https://labproducts.caredx.com> for  
“Instructions for Use” (IFU)

Lot No.: **0R2**

Lot-specific Information  
**PRIMER SPECIFICATION**

Well No.	1	2	3	4	5	6	7	8	9	10	11	12
Length of spec. PCR product	165	205	210	155	150	80	90	85	180	150	215	190
					245	185	175					
						270						
Length of int. pos. control <sup>1</sup>	800	800	800	1070	1070	1070	1070	800	1070	1070	800	800
5'-primer(s) <sup>2</sup>	414 5'-gAA 3'	363 5'-ATA 3'	363 5'-ATA 3'	123 5'-AgT 3'	123 5'-AgT 3'	123 5'-AgT 3'	103 5'-CCT 3'	367 5'-TgC 3'	98 5'-CTC 3'	127 5'-ggg 3'	98 5'-CTC 3'	363 5'-ATA 3'
					414 5'-gAA 3'	385 5'-ggT 3'	362 5'-ggT 3'					
3'-primer(s) <sup>3</sup>	538 5'-CAA 3'	526 5'-CCA 3'	526 5'-CCg 3'	238 5'-CCC 3'	325 5'-gTg 3'	163 5'-CgC 3'	238 5'-CCT 3'	411 5'-TCA 3'	238 5'-CCT 3'	238 5'-CCT 3'	270 5'-ACA 3'	505 5'-gCT 3'
			535 5'-CTA 3'		524 5'-CAT 3'	265 5'-CCC 3'	411 5'-TCA 3'					524 5'-CAC 3'
			538 5'-Cag 3'			616 5'-CgC 3'						

Well No.	13	14	15	16	17	18	19	20	21	22	23	24
Length of spec. PCR product	160	210	245	235	225	140	135	210	150	180	150	105
		270	290	265		210	200	285	185	215		160
							235					210
Length of int. pos. control <sup>1</sup>	1070	1070	800	1070	1070	800	1070	800	1070	800	1070	800
5'-primer(s) <sup>2</sup>	117 5'-CCT 3'	123 5'-AgT 3'	363 5'-ATA 3'	363 5'-ATA 3'	98 5'-CTC 3'	123 5'-AgT 3'	123 5'-AgT 3'	363 5'-ATA 3'	410 5'-gTg 3'	363 5'-ATA 3'	127 5'-gAT 3'	123 5'-AgT 3'
	123 5'-AgT 3'	385 5'-ggT 3'		784 5'-ggA 3'			650 5'-CCC 3'		634 5'-CAg 3'		412 5'-ATT 3'	
				808 5'-CgT 3'					680 5'-gTT 3'		413 5'-CCg 3'	
3'-primer(s) <sup>3</sup>	238 5'-CCT 3'	292 5'-gTg 3'	563 5'-Cgg 3'	586 5'-CAC 3'	282 5'-gAC 3'	212 5'-gCC 3'	206 5'-CA 3'	530 5'-CCT 3'	526 5'-CCA 3'	494 5'-TCC 3'	238 5'-CCT 3'	187 5'-g.C 3'
		616 5'-CgC 3'	572 5'-gCg 3'	899 5'-ACA 3'		227 5'-CTg 3'	227 5'-CTg 3'	595 5'-CCT 3'	777 5'-gCA 3'	513 5'-TCC 3'	526 5'-CCA 3'	240 5'-ggA 3'
		614 5'-TgA 3'				289 5'-AgC 3'	281 5'-ACC 3'	614 5'-TgA 3'		535 5'-CTA 3'		282 5'-gAC 3'
						294 5'-CgT 3'	845 5'-AgT 3'					299 5'-TCg 3'

Well No.	25	26	27	28	29	30	31
Length of spec. PCR product	160	80	145	130	130	80	200
	235	190	195	465	190	155	
		300	465				
Length of int. pos. control <sup>1</sup>	1070	1070	1070	1070	1070	1070	1070
5'-primer(s) <sup>2</sup>	127 5'-gAT 3'	363 5'-ATA 3'	176 5'-gCA 3'	412 5'-ATg 3'	363 5'-ATA 3'	412 5'-ATT 3'	355 5'-CCC 3'
	397 5'-gCC 3'	627 5'-CCC 3'	414 5'-gAA 3'	3 <sup>rd</sup> I 5'-A 3'		485 5'-CAC 3'	373 5'-gCC 3'
	808 5'-CgT 3'		3 <sup>rd</sup> I 5'-A 3'				
3'-primer(s) <sup>3</sup>	238 5'-CCT 3'	403 5'-gCT 3'	282 5'-gAC 3'	502 5'-CTT 3'	453 5'-TCT 3'	526 5'-CCA 3'	526 5'-CCg 3'
	526 5'-CCA 3'	514 5'-CTA 3'	570 5'-CAg 3'	621 5'-ggg 3'	454 5'-CTA 3'		
	899 5'-ACA 3'	886 5'-CAT 3'	621 5'-ggg 3'		513 5'-TCC 3'		
					514 5'-CTA 3'		



0197

For *In Vitro* Diagnostic Use  
MA123 v01 SSP PI Template  
Date: April 2022 Rev. No: 00

**101.429-12 – including *Taq* polymerase, IFU-01**  
**101.429-12u – without *Taq* polymerase, IFU-02**

Visit <https://labproducts.caredx.com> for  
**“Instructions for Use” (IFU)**

**Lot No.: 0R2**

**Lot-specific Information**

<sup>1</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

<sup>2</sup>The nucleotide position matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>3</sup>The nucleotide position matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.



**0197**

For *In Vitro* Diagnostic Use  
 MA123 v01 SSP PI Template  
 Date: April 2022 Rev. No: 00

101.429-12 – including *Taq* polymerase, IFU-01  
 101.429-12u – without *Taq* polymerase, IFU-02

Visit <https://labproducts.caredx.com> for  
 “Instructions for Use” (IFU)

Lot No.: **0R2**

Lot-specific Information

CELL LINE VALIDATION SHEET																				
HLA-A*30 SSP subtyping kit <sup>2</sup>																				
				Well																
				1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	
				Prod. No.:	201899801	201899802	201899803	201899804	201899805	201899806	202240507	201899808	201899809	201899810	201899811	201899812	201899813	201899814	202240515	201899816
	IHWC cell line <sup>1</sup>	A*	A*																	
1	9001 SA	*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	9280 LK707	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3	9011 E4181324	*01:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4	9275 GU373	*30:01		+	+	-	-	-	-	-	-	+	-	+	-	+	-	-	-	-
5	9009 KAS011	*01:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
6	9353 SM	*02:01	*26:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7	9020 QBL	*26:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
8	9025 DEU	*31:01		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
9	9026 YAR	*26:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	9107 LKT3	*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	9051 PITOUT	*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	9052 DBB	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
13	9004 JESTHOM	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	9071 OLGA	*31:01		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
15	9075 DKB	*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
16	9037 SWEIG007	*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
17	9282 CTM3953540	*03:01	*80:01	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18	9257 32367	*33:03	*74:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
19	9038 BM16	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
20	9059 SLE005	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
21	9064 AMALA	*02:17		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
22	9056 KOSE	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
23	9124 IHL	*02:01	*34:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
24	9035 JBUSH	*32:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
25	9049 IBW9	*33:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
26	9285 WT49	*02:05		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
27	9191 CH1007	*24:10	*29:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
28	9320 BEL5GB	*02:01	*29:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
29	9050 MOU	*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
30	9021 RSH	*30:01	*68:02	+	+	-	-	-	-	-	-	+	-	+	-	+	-	-	-	-
31	9019 DUCAF	*30:02		+	-	+	-	-	-	-	-	+	-	+	-	+	-	-	-	-
32	9297 HAG	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
33	9098 MT14B	*31:01		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
34	9104 DHIF	*31:01		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
35	9302 SSTO	*32:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
36	9024 KT17	*02:06	*11:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
37	9065 HHKB	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
38	9099 LZL	*02:17		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
39	9315 CML	*01:01	*03:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
40	9134 WHONP199	*02:07	*30:01	+	+	-	-	-	-	-	-	+	-	+	-	+	-	-	-	-
41	9055 H0301	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
42	9066 TAB089	*02:07		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
43	9076 T7526	*02:06	*02:07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
44	9057 TEM	*66:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
45	9239 SHJO	*23:01	*24:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
46	9013 SCHU	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
47	9045 TUBO	*02:16	*03:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
48	9303 TER-ND	*02:01	*11:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-



0197

101.429-12 – including *Taq* polymerase, IFU-01  
 101.429-12u – without *Taq* polymerase, IFU-02

Visit <https://labproducts.caredx.com> for  
 “Instructions for Use” (IFU)

Lot No.: **0R2**

Lot-specific Information

CELL LINE VALIDATION SHEET																			
HLA-A*30 SSP subtyping kit <sup>2</sup>																			
				Well															
				17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	
				Prod. No.:	201899817	202240518	202240519	202240520	201899821	201899822	201899823	201899824	201899825	201899826	201899827	202240528	201899829	201899830	201899831
	IHWC cell line <sup>1</sup>	A*	A*																
1	9001 SA	*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
2	9280 LK707	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
3	9011 E4181324	*01:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
4	9275 GU373	*30:01		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
5	9009 KAS011	*01:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
6	9353 SM	*02:01	*26:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
7	9020 QBL	*26:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
8	9025 DEU	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
9	9026 YAR	*26:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
10	9107 LKT3	*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
11	9051 PITOUT	*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
12	9052 DBB	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
13	9004 JESTHOM	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
14	9071 OLGA	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
15	9075 DKB	*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
16	9037 SWEIG007	*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
17	9282 CTM3953540	*03:01	*80:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
18	9257 32367	*33:03	*74:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
19	9038 BM16	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
20	9059 SLE005	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
21	9064 AMALA	*02:17		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
22	9056 KOSE	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
23	9124 IHL	*02:01	*34:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
24	9035 JBUSH	*32:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
25	9049 IBW9	*33:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
26	9285 WT49	*02:05		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
27	9191 CH1007	*24:10	*29:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
28	9320 BEL5GB	*02:01	*29:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
29	9050 MOU	*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
30	9021 RSH	*30:01	*68:02	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
31	9019 DUCAF	*30:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
32	9297 HAG	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
33	9098 MT14B	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
34	9104 DHIF	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
35	9302 SSTO	*32:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
36	9024 KT17	*02:06	*11:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
37	9065 HHKB	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
38	9099 LZL	*02:17		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
39	9315 CML	*01:01	*03:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
40	9134 WHONP199	*02:07	*30:01	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
41	9055 H0301	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
42	9066 TAB089	*02:07		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
43	9076 T7526	*02:06	*02:07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
44	9057 TEM	*66:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
45	9239 SHJO	*23:01	*24:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
46	9013 SCHU	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
47	9045 TUBO	*02:16	*03:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
48	9303 TER-ND	*02:01	*11:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	



0197

For *In Vitro* Diagnostic Use  
 MA123 v01 SSP PI Template  
 Date: April 2022 Rev. No: 00

**101.429-12 – including Taq polymerase, IFU-01**  
**101.429-12u – without Taq polymerase, IFU-02**

Visit <https://labproducts.caredx.com> for  
**“Instructions for Use” (IFU)**

**Lot No.: 0R2**

**Lot-specific Information**

<sup>1</sup>The provided cell line HLA specificities are retrieved from the <http://www.ihwg.org/hla> web site. The specificity of an individual cell line may thus be subject to change.

<sup>2</sup>The specificity of each primer solution in the kit has been tested against 48 well characterized cell line DNAs and where applicable, additional cell line DNAs.

No DNAs carrying the alleles to be amplified by primer solutions 6, 7, 14 to 16, 18 to 26 and 28 to 31 were available. The specificities of the primers in primer 6, 7, 14 to 16, 23 to 25 and 28 to 31 were tested by separately adding one, two or three additional 5'-primers, respectively one or two additional 3'-primers.

In primer solutions 18 to 20, 22 and 26 it was only possible to test the 5'-primers, the 3'-primers were not possible to be tested.

In primer solution 21 it was only possible to test the 3'-primers, the 5'-primers were not possible to be tested.

In primer solutions 7, 16, 23, 25, 30 and 31 one or two 5'-primers were not possible to be tested.

In primer solutions 2, 3, 5, 6, 12, 14 to 16, 24, and 27 to 29 one, two, three or four 3'-primers were not possible to be tested.

In addition, one or more primers in primer solutions 5, 13 and 27 were tested by separately adding 5'- and/or 3'-primers.



**0197**

For *In Vitro* Diagnostic Use  
 MA123 v01 SSP PI Template  
 Date: April 2022 Rev. No: 00



101.429-12 – including *Taq* polymerase, IFU-01  
101.429-12u – without *Taq* polymerase, IFU-02

Visit <https://labproducts.caredx.com> for  
“Instructions for Use” (IFU)

Lot No.: **0R2**

Lot-specific Information

## ADDRESSES:

### Manufacturer:

**CareDx AB**, Franzengatan 5, SE-112 51 Stockholm, Sweden.

Tel: +46-8-508 939 00

**Fax:** +46-8-717 88 18

**E-mail:** [orders-se@caredx.com](mailto:orders-se@caredx.com)

**Web page:** <https://labproducts.caredx.com/>

**CareDx Lab Solutions Inc.**, 901 S. Bolmar St., Suite R, West Chester, PA 19382

**Tel:** 1-877-653-78171

**Fax:** 610-344-7989

**E-mail:** [orders-us@caredx.com](mailto:orders-us@caredx.com)

**Web page:** <https://labproducts.caredx.com/>

For information on CareDx distributors worldwide, contact **CareDx AB**.



**0197**

For *In Vitro* Diagnostic Use

MA123 v01 SSP PI Template

Date: April 2022 Rev. No: 00